Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telaprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 13/20 | 1.00 |
| ▸ | CTSL | P07711 | 8/20 | 1.00 |
| ▸ | CTSK | P43235 | 6/20 | 1.00 |
| ▸ | CTSS | P25774 | 3/20 | 1.00 |
| ▸ | ELANE | P08246 | 2/20 | 1.00 |
| ▸ | CTSV | O60911 | 1/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | CMA1 | P23946 | 1/20 | 1.00 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.90 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telaprevir SCHEMBL184177 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL19187546 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201921 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13219678 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13219647 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201959 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13201901 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL13219193 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL22171584 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE | |
| Telaprevir SCHEMBL22171583 | 1.00 | CTSB (1.00) | CTSBCTSLCTSKCTSSELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420122-B2 | 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide; Solvent-anti-solvent precipitation; hepatitis C virus protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420122-B2 | 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide; Solvent-anti-solvent precipitation; hepatitis C virus protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120294935-A1 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0] HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME | ZARKADAS DIMITRIOS (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2428204-A2 | pH sensitive matrix formulation | Schering Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20100081672-A1 | PH SENSITIVE MATRIX FORMULATION | SCHERING CORPORATION | 2010-04-01 | — | — | US | disclosed |
| US-20100081672-A1 | PH SENSITIVE MATRIX FORMULATION | SCHERING CORPORATION | 2010-04-01 | — | — | US | disclosed |
| US-20080254128-A1 | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | disclosed |
| US-20080254128-A1 | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | disclosed |
| US-20080193518-A1 | Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same | SCHERING CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080193518-A1 | Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same | SCHERING CORPORATION | 2008-08-14 | — | — | US | disclosed |
| WO-2007139585-A1 | CONTROLLED-RELEASE FORMULATION | SCHERING CORPORATION (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007127380-A2 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0] HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME | SCHERING CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193518-A1 | Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same | AZI2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1 | CTSB 2896/4885CTSL 3868/4885CTSK 3775/4885 |
| US-20120294935-A1 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0] HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME | AZI2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1 | CTSB 2824/4885CTSL 3504/4885CTSK 3518/4885 |
| US-20080254128-A1 | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same | AZI2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1 | CTSB 2824/4885CTSL 3504/4885CTSK 3518/4885 |
| US-20100081672-A1 | PH SENSITIVE MATRIX FORMULATION | SI, HRH2, TMPRSS15 | CTSB 645/4885CTSL 722/4885CTSK 470/4885 |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | CTSV, AKR1B1, AKR1A1 | CTSB 14/4885CTSL 12/4885CTSK 10/4885 |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | CTRL, PEPD, PRCP | CTSB 55/4885CTSL 106/4885CTSK 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.